Tecentriq

CONTENTS

6 OVERVIEW
6 Drug Overview
7 Product Profiles
7 Tecentriq : Hepatocellular carcinoma (HCC)
16 Tecentriq : Renal cell carcinoma (RCC)
27 Tecentriq : Non-small cell lung cancer (NSCLC)
45 Tecentriq : Melanoma
58 Tecentriq : Prostate cancer
68 Tecentriq : Colorectal cancer (CRC)
82 Tecentriq : Ovarian cancer
92 Tecentriq : Bladder cancer
104 atezolizumab : Breast cancer: triple-negative

LIST OF FIGURES
11 Figure 11: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
12 Figure 12: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
14 Figure 13: Tecentriq sales for melanoma across the US and five major EU markets, by country, 2017–26
21 Figure 14: Tecentriq for prostate cancer – SWOT analysis
22 Figure 15: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
23 Figure 6: Datamonitor Healthcare’s drug assessment summary of Tecentriq for RCC
25 Figure 16: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
36 Figure 17: Tecentriq for colorectal cancer – SWOT analysis
37 Figure 9: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
38 Figure 10: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
40 Figure 18: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
50 Figure 19: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
52 Figure 20: Tecentriq for ovarian cancer – SWOT analysis
54 Figure 21: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
61 Figure 22: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
62 Figure 23: Tecentriq for urothelial bladder cancer – SWOT analysis
63 Figure 24: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
65 Figure 25: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
73 Figure 26: Atezolizumab for triple-negative breast cancer – SWOT analysis
74 Figure 20: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
75 Figure 27: Datamonitor Healthcare’s drug assessment summary of atezolizumab for triple-negative breast cancer
77 Figure 28: Datamonitor Healthcare’s drug assessment summary of atezolizumab for triple-negative breast cancer
88 Figure 23: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
89 Figure 24: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
98 Figure 25: Tecentriq for urothelial bladder cancer – SWOT analysis
99 Figure 1: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for HCC
100 Figure 27: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
109 Figure 2: HCC sales in the US, 2018–27
110 Figure 3: HCC sales in Japan, 2018–27
111 Figure 30: Datamonitor Healthcare’s drug assessment summary of atezolizumab for triple-negative breast cancer

LIST OF TABLES
7 Table 1: Recent high-impact events for Tecentriq in HCC
8 Table 2: Tecentriq drug profile
9 Table 3: Trials of Tecentriq for HCC
10 Table 4: Tecentriq for HCC – SWOT analysis
17 Table 5: Tecentriq drug profile
18 Table 6: Tecentriq Phase III data in RCC
20 Table 7: Tecentriq Phase III trials in RCC
26 Table 8: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
27 Table 9: Tecentriq drug profile
29 Table 10: Tecentriq pivotal trial data in non-small cell lung cancer
31 Table 11: Tecentriq late-phase trial data in non-small cell lung cancer
34 Table 12: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
41 Table 13: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
43 Table 14: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
46 Table 15: Tecentriq drug profile
47 Table 16: Tecentriq ongoing late-phase trials in melanoma
49 Table 17: Tecentriq early-phase data in melanoma
55 Table 18: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
57 Table 19: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
58 Table 20: Tecentriq drug profile
60 Table 21: Tecentriq Phase III trials in prostate cancer
66 Table 22: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
68 Table 23: Tecentriq drug profile
70 Table 24: Tecentriq Phase III trial in colorectal cancer
72 Table 25: Tecentriq early-phase data in colorectal cancer
78 Table 26: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
80 Table 27: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
83 Table 28: Tecentriq drug profile
84 Table 29: Tecentriq Phase III trials in ovarian cancer
86 Table 30: Overview of Phase I data for Tecentriq in ovarian cancer
93 Table 31: Tecentriq drug profile
95 Table 32: Tecentriq pivotal trial data in urothelial bladder cancer
96 Table 33: Tecentriq ongoing late-phase trials in urothelial bladder cancer
105 Table 34: Atezolizumab drug profile
106 Table 4: HCC – current and future forecast trends
107 Table 36: Atezolizumab Phase Ib data in triple-negative breast cancer
108 Table 37: Atezolizumab Phase I data in triple-negative breast cancer